BMJ 2002;324:1361-1364 ( 8 June )

Papers

Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis

Aloysius L D'Souza, research fellow, Chakravarthi Rajkumar, senior lecturer and honorary consultant, Jonathan Cooke, statistician, Christopher J Bulpitt, professor of geriatric medicine. 

Care of the Elderly Section, Faculty of Medicine, Imperial College School of Medicine, Hammersmith Hospital, London W12 0NN

Correspondence to: A L D'Souza aloysius.dsouza{at}ic.ac.uk


    Abstract
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References

Objective: To evaluate efficacy of probiotics in prevention and treatment of diarrhoea associated with the use of antibiotics.
Design: Meta-analysis; outcome data (proportion of patients not getting diarrhoea) were analysed, pooled, and compared to determine odds ratios in treated and control groups.
Identification: Studies identified by searching Medline between 1966 and 2000 and the Cochrane Library.
Studies reviewed: Nine randomised, double blind, placebo controlled trials of probiotics.
Results: Two of the nine studies investigated the effects of probiotics in children. Four trials used a yeast (Saccharomyces boulardii), four used lactobacilli, and one used a strain of enterococcus that produced lactic acid. Three trials used a combination of probiotic strains of bacteria. In all nine trials, the probiotics were given in combination with antibiotics and the control groups received placebo and antibiotics. The odds ratio in favour of active treatment over placebo in preventing diarrhoea associated with antibiotics was 0.39 (95% confidence interval 0.25 to 0.62; P<0.001) for the yeast and 0.34 (0.19 to 0.61; P<0.01) for lactobacilli. The combined odds ratio was 0.37 (0.26 to 0.53; P<0.001) in favour of active treatment over placebo.
Conclusions: The meta-analysis suggests that probiotics can be used to prevent antibiotic associated diarrhoea and that S boulardii and lactobacilli have the potential to be used in this situation. The efficacy of probiotics in treating antibiotic associated diarrhoea remains to be proved. A further large trial in which probiotics are used as preventive agents should look at the costs of and need for routine use of these agents.

What is already known on this topic
Probiotics are well known for their microbiological properties and have been used to treat gastrointestinal and vaginal mucosal infections

Conflicting results have prevented probiotics from being accepted as viable alternatives to conventional treatments for antibiotic associated diarrhoea

The commercial availability of probiotics is increasing

What this study adds
Probiotics may prevent antibiotic associated diarrhoea

The potential of specific probiotics to prevent Clostridium difficile infection secondary to the use of antibiotics should be re-examined

A large trial looking at the efficacy of probiotics in preventing antibiotic associated diarrhoea, particularly in elderly patients, with an emphasis on the optimal dose and cost benefits is needed




    Introduction
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References

The term "probiotic" was first used to describe "a live microbial supplement, which beneficially affects the host by improving its microbial balance."1 Since then, research has looked at possible clinical uses for these agents. In 1995, when a greater understanding of their properties had developed, the term "biotherapeutic agents" was proposed to describe micro-organisms with specific therapeutic properties that also inhibit the growth of pathogenic bacteria.2

Probiotics and their uses

  • Probiotics are live organisms that improve the microbial balance of the host
  • Probiotics have special properties that make them useful in fighting infections of mucosal surfaces such as the gut and vagina
  • Different species of lactobacilli and the yeast Saccharomyces boulardii have the potential for use in clinical practice
  • Probiotics are becoming increasingly available as capsules and dairy based food supplements sold in health food stores and some supermarkets
  • The relative lack of side effects makes probiotics a possible way of preventing antibiotic associated diarrhoea

A number of agents have been isolated and studied with a view to clinical use. Streptococcus thermophilus and Lactobacillus bulgaricus, commonly used in the dairy food industry, were among the first to be studied. Other strains that have been used are Bifidobacterium bifidum, B longum, Enterococcus faecium, Saccharomyces boulardii, L acidophilus, L casei, and Lactobacillus GG. However, doctors are still reluctant to use these agents in clinical practice.

In this paper, we review the results from various trials carried out to study their benefits. We also look at the properties of biotherapeutic agents and options for further research.


    Materials and methods
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References

Literature search
We searched Medline between 1966 to 2000 with the terms "probiotics," "biotherapeutic agents," "lactobacilli," "antibiotic associated diarrhoea," and "Clostridium difficile." We also searched the Cochrane Controlled Trials Register and the Cochrane Database of Systematic Reviews. We included all randomised double blind trials that compared the effects of probiotic therapy and placebo (both given in combination with antibiotics).

Ten double blind placebo controlled trials were relevant to our area of interest (nine published in English and one in French).3-12 Our meta-analysis included nine that looked at prevention of diarrhoea. We excluded the other trial, which looked at treatment of diarrhoea.12

Meta-analysis and data abstraction
The meta-analysis was carried out according to the recommendations of the QUOROM statement.13 The key outcome data taken for analysis included the sample size, treatment regimens, and numbers of patients in both arms of the study who had an absence of diarrhoea (table 1).


                              
View this table:
[in this window]
[in a new window]
 

Table 1. Probiotics studied in trials and patients with absence of diarrhoea at end of trial




    Results
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References

Nine trials were included in the final analysis (fig 1). The study regimens used probiotics combined with one antibiotic or a variety of antibiotics (table 1). All trials studied the efficacy of a probiotic in the prevention of antibiotic associated diarrhoea. The numbers of patients and the duration of follow up varied greatly from study to study, but the patients' characteristics were similar for the active treatment and placebo groups within each study.



View larger version (33K):
[in this window]
[in a new window]
  		Fig 1.   Meta-analysis profile summarising trial flow. RCT=randomised controlled trial

We calculated the odds ratio on the basis of the proportion of patients free of diarrhoea on treatment compared with that in control groups. After tests of homogeneity, summary odds ratios and 95% confidence interval limits were provided for the combined data of the four trials that used S boulardii (yeast trials), the five non-yeast trials, and all nine trials together. The combined odds ratios for the four yeast trials and for the five non-yeast trials were similar (0.39 (95% confidence interval 0.25 to 0.62) and 0.34 (0.19 to 0.61), respectively); both favoured active treatment over placebo in the prevention of antibiotic associated diarrhoea. The odds ratio for pooled data from all nine trials was in favour of active treatment over placebo in the prevention of antibiotic associated diarrhoea (0.37; 0.26 to 0.53). Six studies showed a significant benefit of probiotic treatment compared with placebo (P<0.05) (fig 2). 3 5 6 8 9 11 One study showed benefit for only a subgroup of patients who did not receive non-antibiotic drugs likely to induce diarrhoea, such as magnesium hydroxide (for constipation), lactulose, and bisacodyl (for hepatic encephalopathy).4



View larger version (28K):
[in this window]
[in a new window]
  		Fig 2.   Plot of the log of odds ratios for the proportion of patients free of diarrhoea in treatment groups compared with control groups



    Discussion
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References

Our meta-analysis of trials that used live organisms to prevent diarrhoea associated with antibiotics shows that probiotics may be effective in preventing antibiotic associated diarrhoea. We had only a small number of trials in our meta-analysis, and it should be noted that the different antibiotics used in the trials may have altered the risk of patients getting diarrhoea and their response to the probiotics. Although probiotics have been used to prevent or treat diarrhoea of other causes---namely traveller's diarrhoea and infantile infectious diarrhoea---we did not include trials that investigated probiotics in these indications; however, most of these studies showed positive results, and some reviews have been encouraging.14

The way in which probiotics affect the gut has drawn much interest. To combat the problems of gastrointestinal infection, probiotics must be non-pathogenic and must act against pathogens by different mechanisms from antibiotics---for example, by competition. More importantly, they should have a fairly rapid onset of action and survive the challenges of gastric acid, bile, or concurrent antibiotics. It is also desirable that they modify immune processes to destroy the invading organism. Saccharomyces boulardii and lactobacilli display these common properties.

A few live organisms have been used in many trials. S boulardii, a non-pathogenic yeast, is one such organism. It has a growth temperature of 37°C, rapidly colonises the bowel, does not alter the normal gut flora, and is cleared from the colon after treatment is discontinued.15 Of the four yeast trials, three studies individually showed significant benefit, 3 5 9 but one did not10; differences in the dose and duration of treatment with S boulardii and variations in the period of follow up may explain this disparity. Interestingly, S boulardii can also destroy the receptor site for C difficile toxin A and B by producing a protease16; this could explain how S boulardii was noted to reduce the frequency of toxin B positivity.12

The other probiotic agent used widely in clinical trials is the Lactobacillus species. The mechanism of action of lactobacilli may be through multiple means: Lactobacillus GG has shown beneficial effects on intestinal immunity; it increases the numbers of cells that secrete immunoglobulin A and other immunoglobulins in the intestinal mucosa, and it stimulates the local release of interferon.17 It also facilitates antigen transport to underlying lymphoid cells, and shows increased uptake in Peyer's patches.17 Lactobacillus GG has also been shown to produce an antimicrobial substance that inhibits the growth of Escherichia coli, streptococci, Clostridium difficile, Bacteroides fragilis, and Salmonella.18 L casei shirota also showed good survival in the gut in separate studies, and mucosal antibody titres (specific to lactobacilli) were increased in the presence of this agent. 19 20 Although there was no discernible change to the numbers of clostridia or enterococci, there was an increase in the numbers of excreted bifidobacteria---a normal bowel anaerobe. 19 20 It is possible that this increase in bifidobacteria interferes with the pathogenic potential of C difficile.

Probiotics are a possible solution in the prevention of antibiotic-associated diarrhoea. Clostridium difficile infection is increasingly prevalent in today's hospital setting, particularly in elderly patients, in whom 10-20% of such cases occur.21 The incidence of antibiotic associated diarrhoea depends on the antibiotic used and each individual patient's risk factors. The standard regimens to treat colitis associated with Clostridium difficile are metronidazole and vancomycin; although these drugs are successful in 80% of cases, about 20% of patients suffer from recurrence.22 In light of the need to control costs in these days of managed health care, we must re-examine the benefits of using live organisms. Whether the use of probiotics can actually reduce the length of hospital stay by reducing the incidence of infection with C difficile and the need to use antibiotics such as metronidazole and vancomycin are issues that need to be addressed in a clinical trial.

Conclusion
Our meta-analysis of nine trials shows that biotherapeutic agents may be useful in preventing antibiotic associated diarrhoea.

The increasing availability, lower costs, and relative lack of side effects of probiotics contrast with the problems associated with current antibiotic regimens. Commercially available strains are being marketed in capsules and yoghurt based drinks, but their potential benefit needs further investigation. Data from trials have provided us with clear evidence on the efficacy of some strains in the gut, but we still need to see confirmation of their clinical benefit.
    Acknowledgments

   Contributors: See bmj.com.

    Footnotes

Editorial by Barbut and Meynard

Funding: No funding was sought or obtained for the conduct of this study.

Competing interests: None declared.

The full version of this article appears on bmj.com


    References
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References

1. Fuller RB. Probiotics in human medicine. Gut 1991; 32: 439-442[Free Full Text].
2. McFarland LV, Elmer GW. Biotherapeutic agents: past, present and future. Microecol Ther 1995; 23: 46-73.
3. Adam J, Barret A, Barret-Bellet C. Essais cliniques contrôlés en double insu de l'ultra-levure lyophilisée: étude multicentrique par 25 médicins de 388 cas. Gaz Med Fr 1977; 84: 2072-2078.
4. Gotz V, Romankiewicz JA, Moss J, Murray HW. Prophylaxis against ampicillin associated diarrhoea with Lactobacillus preparation. Am J Hosp Pharm 1979; 36: 754-757[Abstract].
5. Surawicz CM, Elmer GW, Speelman P, McFarland LV, Chinn J, Van Belle G. Prevention of antibiotic associated diarrhoea by Saccharomyces boulardii. Gastroenterology 1989; 96: 981-988[Web of Science][Medline].
6. Wunderlich PF, Braun L, Fumagalli I, D'Apuzzo V, Heim F, Karly M, et al. Double-blind report on the efficacy of lactic acid-producing Enterococcus SF68 in the prevention of antibiotic-associated diarrhoea and in the treatment of acute diarrhoea. J Int Med Res 1989; 17: 333-338[Web of Science][Medline].
7. Tankanow RM, Ross MB, Ertel IJ, Dickinson DG, McCormick LS, Garfinkel JF. Double blind, placebo-controlled study of the efficacy of Lactinex in the prophylaxis of amoxicillin-induced diarrhoea. DICP, Ann Pharm 1990; 24: 382-384.
8. Orrhage K, Brismar B, Nord CE. Effects of supplements of Bifidobacterium longum and Lactobacillus acidophilus on intestinal microbiota during administration of clindamycin. Microb Ecol Health Dis 1994; 7: 17-25.
9. McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Moyer KA, Melcher SA, et al. Prevention of beta -lactam-associated diarrhoea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol 1995; 90: 439-448[Web of Science][Medline].
10. Lewis SJ, Potts LF, Barry RE. The lack of therapeutic effect of S boulardii in the prevention of antibiotic related diarrhoea in elderly patients. J Infect 1998; 36: 171-174[CrossRef][Web of Science][Medline].
11. Vanderhoof JA, Whitney DB, Antonson DL, Hanner TL, Lupo JV, Young RJ. Lactobacillus GG in the prevention of antibiotic-associated diarrhoea in children. J Pediatrics 1999; 135: 564-568[CrossRef][Web of Science][Medline].
12. McFarland LV, Surawicz CM, Greenberg RN, Fekety R, Elmer GW, Moyer KA, et al. A randomized placebo-controlled trial of S boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994; 271: 1913-1918[Abstract/Free Full Text].
13. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF, for the QUOROM Group. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet 1999; 354: 1896-1900[CrossRef][Web of Science][Medline].
14. Elmer GW, Surawicz CM, McFarland LV. Biotherapeutic agents: a neglected modality for treatment and prevention of selected intestinal and vaginal infections. JAMA 1996; 275: 870-876[Abstract/Free Full Text].
15. Blehaut H, Massot J, Elmer GW, Levy RH. Disposition kinetics of S boulardii in man and rat. Biopharm Drug Dispos 1989; 10: 353-364[CrossRef][Web of Science][Medline].
16. Castagliulo I, Riegler MF, Valenick L, LaMont JT, Pothoulakis C. S. boul-ardii protease inhibits effects of C. difficile toxins A and B in human colonic mucosa. Infect Immun 1999; 67: 302-307[Abstract/Free Full Text].
17. Benno Y, He F, Hosada M, Hashimoto H, Kojima T, Yamazaki K, et al. Effects of Lactobacillus GG yoghurt on human intestinal micro-ecology in Japanese subjects. Nutr Today 1996; 31(6 suppl): 9-11S[CrossRef].
18. Gorbach SL. The discovery of Lactobacillus GG. Nutr Today 1996; 31(6 suppl): 2-4S[CrossRef].
19. Spanhaak S, Havenaar R, Schaafsma G. Effect of consumption of milk fermented by Lactobacillus casei shirota on intestinal microflora and immune parameters in humans. Eur J Clin Nutr 1998; 52: 899-907[CrossRef][Web of Science][Medline].
20. Yuki N, Watanabe K, Mike A, Tagami Y, Tanaka R, Ohwaki M, et al. Survival of probiotic Lactobacillus casei shirota in the GI tract-selective isolation using monoclonal antibodies. Int J Food Microbiol 1999; 48: 51-57[CrossRef][Web of Science][Medline].
21. Kelly CP, Pothoulakis C, Lamont JT. Clostridium difficile colitis. N Engl J Med 1994; 330: 257-262[Free Full Text].
22. Walters BAJ, Roberts R, Stafford R, Seneviratne E. Recurrence of antibiotic-associated colitis: endogenous persistence of C difficile during vancomycin therapy. Gut 1983; 24: 206-212[Abstract/Free Full Text].

(Accepted 7 November 2001)

© BMJ 2002
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

Relevant Articles

Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial
Mary Hickson, Aloysius L D'Souza, Nirmala Muthu, Thomas R Rogers, Susan Want, Chakravarthi Rajkumar, and Christopher J Bulpitt
BMJ 2007 335: 80. [Abstract] [Full Text] [PDF]

Probiotics and antibiotic associated diarrhoea
Mark Battle, Lara Teare, Sue Law, Jamie Fulton, John Beckly, Stephen Lewis, A L D'Souza, C Rajkumar, J Cooke, and C J Bulpitt
BMJ 2002 325: 901. [Extract] [Full Text]

Probiotics can prevent diarrhoea
BMJ 2002 324: 0. [Full Text]

Managing antibiotic associated diarrhoea
Frédéric Barbut and Jean Luc Meynard
BMJ 2002 324: 1345-1346. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

  • Merenstein, D. J., Foster, J., D'Amico, F. (2009). A Randomized Clinical Trial Measuring the Influence of Kefir on Antibiotic-Associated Diarrhea: The Measuring the Influence of Kefir (MILK) Study. Arch Pediatr Adolesc Med 163: 750-754 [Abstract] [Full text]  
  • Koretz, R. L. (2009). Probiotics, Critical Illness, and Methodologic Bias. Nutr Clin Pract 24: 45-49 [Abstract] [Full text]  
  • Kelly, C. P., LaMont, J. T. (2008). Clostridium difficile -- More Difficult Than Ever. NEJM 359: 1932-1940 [Full text]  
  • Pildal, J, Hrobjartsson, A, Jorgensen, K., Hilden, J, Altman, D., Gotzsche, P. (2007). Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials. Int J Epidemiol 36: 847-857 [Abstract] [Full text]  
  • Hickson, M., D'Souza, A. L, Muthu, N., Rogers, T. R, Want, S., Rajkumar, C., Bulpitt, C. J (2007). Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 335: 80-80 [Abstract] [Full text]  
  • Segarra-Newnham, M. (2007). Probiotics for Clostridium difficile-Associated Diarrhea: Focus on Lactobacillus rhamnosus GG and Saccharomyces boulardii. The Annals of Pharmacotherapy 41: 1212-1221 [Abstract] [Full text]  
  • de Vrese, M., Marteau, P. R. (2007). Probiotics and Prebiotics: Effects on Diarrhea. J. Nutr. 137: 803S-811S [Abstract] [Full text]  
  • D'Souza, A L (2007). Ageing and the gut. Postgrad. Med. J. 83: 44-53 [Abstract] [Full text]  
  • Surowiec, D., Kuyumjian, A. G, Wynd, M. A, Cicogna, C. E (2006). Past, Present, and Future Therapies for Clostridium difficile-Associated Disease. The Annals of Pharmacotherapy 40: 2155-2163 [Abstract] [Full text]  
  • Johnston, B. C., Supina, A. L., Vohra, S. (2006). Probiotics for pediatric antibiotic-associated diarrhea: a meta-analysis of randomized placebo-controlled trials.. CMAJ 175: 377-383 [Abstract] [Full text]  
  • Boyle, R. J, Robins-Browne, R. M, Tang, M. L. (2006). Probiotic use in clinical practice: what are the risks?. Am. J. Clin. Nutr. 83: 1256-1264 [Abstract] [Full text]  
  • Charrois, T. L., Sandhu, G., Vohra, S. (2006). Probiotics. Pediatr. Rev. 27: 137-139 [Full text]  
  • Kamiya, T, Wang, L, Forsythe, P, Goettsche, G, Mao, Y, Wang, Y, Tougas, G, Bienenstock, J (2006). Inhibitory effects of Lactobacillus reuteri on visceral pain induced by colorectal distension in Sprague-Dawley rats. Gut 55: 191-196 [Abstract] [Full text]  
  • Murphy, C., Vernon, M., Cullen, M. (2006). Intravenous immunoglobulin for resistant Clostridium difficile infection. Age Ageing 35: 85-86 [Abstract] [Full text]  
  • Akobeng, A K (2005). Understanding systematic reviews and meta-analysis. Arch. Dis. Child. 90: 845-848 [Abstract] [Full text]  
  • Tonna, I, Welsby, P D (2005). Pathogenesis and treatment of Clostridium difficile infection. Postgrad. Med. J. 81: 367-369 [Abstract] [Full text]  
  • Johnston, B. C., Vohra, S. (2005). Treating C. difficile. CMAJ 172: 447-448 [Full text]  
  • Van Niel, C. W. (2005). Probiotics: Not Just for Treatment Anymore. Pediatrics 115: 174-177 [Full text]  
  • (2004). Probiotics for gastrointestinal disorders. DTB 42: 85-88 [Abstract] [Full text]  
  • Langlands, S J, Hopkins, M J, Coleman, N, Cummings, J H (2004). Prebiotic carbohydrates modify the mucosa associated microflora of the human large bowel. Gut 53: 1610-1616 [Abstract] [Full text]  
  • Donald, F., Pirner, D. (2004). Review: probiotics reduced diarrhoea at 3 days in children and adults with proven or presumed infectious diarrhoea. Evid. Based Nurs. 7: 107-107 [Full text]  
  • Greenberger, N. J., Sharma, P. (2004). Update in Gastroenterology and Hepatology. ANN INTERN MED 141: 374-380 [Full text]  
  • Gill, H S, Guarner, F (2004). Probiotics and human health: a clinical perspective. Postgrad. Med. J. 80: 516-526 [Abstract] [Full text]  
  • Hamilton-Miller, J M T (2004). Probiotics and prebiotics in the elderly. Postgrad. Med. J. 80: 447-451 [Abstract] [Full text]  
  • Naaber, P., Smidt, I., Stsepetova, J., Brilene, T., Annuk, H., Mikelsaar, M. (2004). Inhibition of Clostridium difficile strains by intestinal Lactobacillus species. J Med Microbiol 53: 551-554 [Abstract] [Full text]  
  • Casburn-Jones, A C, Farthing, M J G (2004). Management of infectious diarrhoea. Gut 53: 296-305 [Full text]  
  • Mai, V., Morris, J. G. Jr. (2004). Colonic Bacterial Flora: Changing Understandings in the Molecular Age. J. Nutr. 134: 459-464 [Abstract] [Full text]  
  • Pickerd, N, Tuthill, D (2004). Resolution of cryptosporidiosis with probiotic treatment. Postgrad. Med. J. 80: 112-113 [Abstract] [Full text]  
  • Reid, G., Jass, J., Sebulsky, M. T., McCormick, J. K. (2003). Potential Uses of Probiotics in Clinical Practice. Clin. Microbiol. Rev. 16: 658-672 [Abstract] [Full text]  
  • Bourlioux, P., Koletzko, B., Guarner, F., Braesco, V. (2003). The intestine and its microflora are partners for the protection of the host: report on the Danone Symposium "The Intelligent Intestine," held in Paris, June 14, 2002. Am. J. Clin. Nutr. 78: 675-683 [Abstract] [Full text]  
  • Hopkins, M. J., Macfarlane, G. T. (2003). Nondigestible Oligosaccharides Enhance Bacterial Colonization Resistance against Clostridium difficile In Vitro. Appl. Environ. Microbiol. 69: 1920-1927 [Abstract] [Full text]  
  • Gagan, M. J. (2003). Review: probiotics are effective in preventing antibiotic associated diarrhoea. Evid. Based Nurs. 6: 16-16 [Full text]  
  • Harris, A. D (2002). Review: probiotics are effective in preventing antibiotic-associated diarrhoea. Evid. Based Med. 7: 184-184 [Full text]  
  • Battle, M., Teare, L., Law, S., Fulton, J., Beckly, J., Lewis, S., D'Souza, A L, Rajkumar, C, Cooke, J, Bulpitt, C J (2002). Probiotics and antibiotic associated diarrhoea. BMJ 325: 901-901 [Full text]  
  • (2002). Probiotic Agents Can Prevent Antibiotic-Associated Diarrhea. JWatch Infect. Diseases 2002: 11-11 [Full text]  
  • (2002). Using Probiotics to Prevent Antibiotic-Associated Diarrhea. JWatch General 2002: 2-2 [Full text]  
  • Barbut, F., Meynard, J. L. (2002). Managing antibiotic associated diarrhoea. BMJ 324: 1345-1346 [Full text]  

Rapid Responses:

Read all Rapid Responses

Brewer's yeast and antibiotic associated diarrhoea
Andy Li
bmj.com, 7 Jun 2002 [Full text]
Misleading presentation of pooled odds ratios
Michael T. Koller
bmj.com, 13 Jun 2002 [Full text]
Probiotics - where's the Cons?
Christopher E Clark
bmj.com, 13 Jun 2002 [Full text]
Probiotic Balance
Bill D. Misner Ph.D.
bmj.com, 21 Jun 2002 [Full text]
Probiotoics and unnatural selection
Mark Battle, et al.
bmj.com, 1 Jul 2002 [Full text]
Access jobs at BMJ Careers
Whats new online at Student BMJ